GlaxoSmithKline Pharmaceuticals Ltd.

Apr 15, 2021 12:15 Source: BSE

GlaxoSmithKline Pharmaceuticals - SEBI Circular No. SEBJ/HO/DDHS/CIR/P/2018/144 Dated November 26,2018 - Fund Raising By Issuance Of Debt Securities By Large Entities

With reference to above circular, we would like to inform you that our Company - GlaxoSmithKline Pharmaceuticals Limited is not a Large Corporate (LC) as per the framework provided in the aforesaid Circular

Apr 15, 2021 12:11 Source: BSE

GlaxoSmithKline Pharmaceuticals - Compliance Of Clause 40(9) Of The Listing Obligations And Disclosure Requirements Regulations, 2015 (LODR)

As required under Clause 40(9) of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), we are enclosing herewith copy of the certificate issued by Manish Ghia & Associates, Practicing Company Secretaries, for the period 1st October 2020 to 31st March 2021, certifying that all certificates have been issued within thirty days of the date of lodgment for transfer, sub-division, consolidation, renewal, exchange or endorsement of calls/allotment monies.

Apr 06, 2021 14:25 Source: BSE

GlaxoSmithKline Pharmaceuticals - Statement Of Investor Complaints For The Quarter Ended March 2021 (Revised)

Apr 06, 2021 12:58 Source: BSE

GlaxoSmithKline Pharmaceuticals - Shareholding for the Period Ended March 31, 2021

GlaxoSmithKline Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here

Apr 06, 2021 10:27 Source: BSE

GlaxoSmithKline Pharmaceuticals - Statement Of Investor Complaints For The Quarter Ended March 2021

Apr 05, 2021 11:28 Source: BSE

GlaxoSmithKline Pharmaceuticals - Compliance Of Clause 7 (3) Of The Listing Obligations And Disclosure Requirements Regulations, 2015 (LODR) For Half Year Ended 31 St March 2021

As required under Clause 7(3) of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), we are enclosing herewith copy of the certificate jointly issued by Company and Company Registrar and Share Transfer Agent M/s Kfintech Private Limited for half year ended 31 st March 2021.

Apr 05, 2021 11:27 Source: BSE

GlaxoSmithKline Pharmaceuticals - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

In Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations,2018, please find enclosed herewith a copy of the Certificate received from Kfintech Private Limited, the Registrar and share Transfer Agent of the Company, for the quarter ended 31 st March 2021 .

Mar 31, 2021 12:30 Source: BSE

GlaxoSmithKline Pharmaceuticals - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment

Approval of Sale of Company''s Manufacturing Facility located at Vemgal, Karnataka

Mar 26, 2021 16:57 Source: BSE

GlaxoSmithKline Pharmaceuticals - Closure of Trading Window

We wish to inform you that the in terms of the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, the trading period for buying or selling of Company''s shares is closed from Monday 29th March 2021and shall reopen on Friday, 21 st May 2021 i.e. after the approval and declaration of Audited Financial Results for the quarter and year ended 31 st March 2021 by the Board of Directors at its meeting scheduled to be held on 18th May 2021 .